First Trust Advisors LP Purchases 42,211 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

First Trust Advisors LP raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,782 shares of the biopharmaceutical company's stock after purchasing an additional 42,211 shares during the quarter. First Trust Advisors LP owned approximately 0.25% of Alnylam Pharmaceuticals worth $77,130,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Allworth Financial LP grew its stake in Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock valued at $140,000 after buying an additional 38 shares during the last quarter. Nixon Peabody Trust Co. increased its stake in shares of Alnylam Pharmaceuticals by 1.9% during the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after purchasing an additional 43 shares during the period. IFP Advisors Inc increased its stake in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares during the period. Nwam LLC boosted its stake in Alnylam Pharmaceuticals by 5.8% in the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after purchasing an additional 50 shares during the period. Finally, National Bank of Canada FI grew its holdings in Alnylam Pharmaceuticals by 9.0% in the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock valued at $157,000 after buying an additional 55 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,984 shares of company stock valued at $16,864,347. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Trading Up 3.7 %

ALNY traded up $8.95 during trading on Friday, reaching $251.56. 835,531 shares of the company's stock were exchanged, compared to its average volume of 876,123. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm has a fifty day moving average price of $247.34 and a two-hundred day moving average price of $256.23. The stock has a market capitalization of $32.72 billion, a PE ratio of -115.93 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Scotiabank increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.